Merck & Co., Inc. (MRK)

NYSE: MRK · Delayed Price · USD
81.54
0.16 (0.20%)
At close: Jan 18, 2022 4:02 PM
80.78
-0.76 (-0.93%)
After-hours:Jan 18, 2022 7:59 PM EST
Market Cap205.97B
Revenue (ttm)49.15B
Net Income (ttm)7.20B
Shares Out2.53B
EPS (ttm)2.83
PE Ratio28.77
Forward PE10.10
Dividend$2.61 (3.20%)
Ex-Dividend DateDec 14, 2021
Volume13,854,431
Open81.10
Previous Close81.38
Day's Range80.80 - 82.16
52-Week Range68.44 - 91.40
Beta0.50
AnalystsBuy
Price Target92.50 (+13.4%)
Earnings DateOct 28, 2021

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected ide...

IndustryPharmaceuticals
Founded2000
CEOKenneth Frazier
Employees73,000
Stock ExchangeNYSE
Ticker SymbolMRK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for Merck & Co. stock is "Buy." The 12-month stock price forecast is 92.50, which is an increase of 13.44% from the latest price.

Price Target
$92.50
(13.44% upside)
Analyst Consensus: Buy

News

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients Wit...

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Significantly Improved Overall Survival (OS) in Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib

11 hours ago - Business Wire

Final Trades: Wynn, Goldman Sachs, Merck & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols:GSWYNN
14 hours ago - CNBC Television

Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges and Psychological Distre...

MADISON, N.J., Jan. 18, 2022 /PRNewswire/ -- Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J.

20 hours ago - PRNewsWire

Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022

Merck MRK, +0.07% and partner privately held Ridgeback Biotherapeutics said Tuesday they have won a supply agreement from the United Nations Children's Fund, or Unicef, to provide it with up to 3 millio...

21 hours ago - Market Watch

Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-1...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine

21 hours ago - Business Wire

4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes

Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in you...

Other symbols:ABBVPFE
1 day ago - Zacks Investment Research

How Do Pfizer's and Merck's COVID Pills Work?

The two oral COVID-19 therapies use completely different mechanisms to fight the coronavirus.

Other symbols:PFE
2 days ago - The Motley Fool

2 Top Healthcare Stocks to Buy Right Now

Don't wait too long to buy shares of these two companies.

Other symbols:VIR
4 days ago - The Motley Fool

Merck Snags Yet Another Indication for This Drug Combo

The company's blockbuster cancer drug Keytruda was approved in Japan to treat patients with certain types of endometrial cancer.

4 days ago - The Motley Fool

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Merck (MRK) closed the most recent trading day at $81.20, moving -0.58% from the previous trading session.

6 days ago - Zacks Investment Research

Omicron-specific vaccines are ‘already priced into COVID stocks': Jefferies Managing Director

Jefferies Managing Director Michael Yee joins Yahoo Finance Live's Julie Hyman and Brian Sozzi to discuss the biotech sector, outlook for M&A activity, and the outlook for COVID-19 stocks.

Other symbols:ABTBMYJNJLLYPFE
1 week ago - Yahoo Finance

Merck (MRK) Keytruda Betters Survival in Adjuvant Lung Cancer

Merck's (MRK) phase III study evaluating Keytruda for adjuvant stage IB-IIIA non-small cell lung cancer (NSCLC) meets one of its dual primary endpoints of disease-free survival (DFS).

1 week ago - Zacks Investment Research

Gilead (GILD) Partners With Merck for Keytruda in NSCLC Study

Gilead (GILD) and Merck collaborate to evaluate the former's breast cancer drug in combination with the latter's blockbuster drug Keytruda for NSCLC study.

Other symbols:GILD
1 week ago - Zacks Investment Research

Here's A Better Pharmaceutical Pick Over Merck Stock

We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer, Merck stock (NYSE: MRK), given its better growth prospects and comparatively lower valuatio...

1 week ago - Forbes

Final Trades: Goldman Sachs, Abbvie, Merck & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols:ABBVFBGSINTC
1 week ago - CNBC Television

Absci (ABSI) Inks Research Agreement With Merck, Stock Up

Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.

Other symbols:ABSI
1 week ago - Zacks Investment Research

Merck's Keytruda As Adjuvant Treatment Improves Disease-Free Survival In Lung Cancer Setting

Merck & Co Inc (NYSE: MRK) has announced that the Phase 3 KEYNOTE-091 trial, investigating Keytruda, met one of its dual primary endpoints in NSCLC patients following surgical resection regardless of PD...

1 week ago - Benzinga

Merck's KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placeb...

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Showed Significant Improvement in Disease-Free Survival as Adjuvant Treatment for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression

1 week ago - Business Wire

3 Big FDA Approvals to Watch For in Q1 2022

Some of the world's biggest drugmakers have important dates with the FDA coming up soon.

Other symbols:AZNBMYLLY
1 week ago - The Motley Fool

Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3

1 week ago - Business Wire

Absci Corp up 50% after announcing research collaboration with Merck

Absci Corporation (NASDAQ: ABSI) went up 50% after it announced that it had executed a research and collaboration agreement with Merck, commonly referred to as MSD outside Canada and the US. The company...

Other symbols:ABSI
1 week ago - Invezz

3 Dow Stocks to Buy Hand Over Fist in January

These Dow stocks provide investors with safe and growing payouts at reasonable valuations.

Other symbols:MCDVZ
1 week ago - The Motley Fool

Jim Cramer's 2022 forecast for3M

"There are a few comeback stories in the dogs of the Dow, but for the most part I don't expect these dogs to have their day in 2022," the "Mad Money" host said.

Other symbols:AMGNBADISDOWHONMMMVVZ
1 week ago - CNBC

Market Recap Wednesday, January 5: Stocks close at lows

Technology stocks came under renewed pressure on Wednesday while the Dow Jones Industrial Average pulled back from a fresh record high. Darrell Cronk, Wells Fargo CIO of Wealth & Investment Management a...

Other symbols:HONINTCWBAWMT
1 week ago - Yahoo Finance

There's absolutely Covid stock fatigue, says Jefferies' Michael Yee

Michael Yee, managing director covering healthcare equity research at Jefferies, joins CNBC's 'Squawk Box' to discuss shares of Covid-19 drugmakers Moderna and Pfizer.

Other symbols:BNTXMRNAPFE
1 week ago - CNBC Television